Skip to main content

elmiron hcp logo

Prescribing Information

FOR US HEALTHCARE PROFESSIONALS

IC Connect Registration Logo

JanssenMD Logo

  • ABOUT INTERSTITIAL CYSTITIS
    • IC Overview
    • Patient Evaluation
    • Mimicking Conditions
  • ABOUT ELMIRON®
    • ELMIRON® and IC
    • Proven Efficacy
    • Dosing Information
  • PATIENT SUPPORT
    • Patient Counseling
    • Counseling Materials
    • Follow Up
    • Managed Care
    • Additional Resources
  • PRACTICE RESOURCES
    • IC Connect
    • Treatment Journey Tool
  • Important Safety Information
  • Prescribing Information
  • Contact Us
  • Patients
  • For US Healthcare Professionals Only

Counseling Materials

Healthcare Professional Photo

Healthcare Professional Photo

The information available here may help you counsel patients about interstitial cystitis (IC). It is important that patients are counseled about their condition and about realistic IC treatment expectations in order to increase the chances of treatment success.1

FILE TITLE

DESCRIPTION

Document icon

Patient Education Flyer

This flyer provides information to educate patients about IC and treatment with ELMIRON®.

Document icon

Journey to Relief ®
Easy to enroll and absolutely FREE

This e-newsletter series offers helpful guidance for those who are just starting treatment. It also delivers helpful patient materials, including savings cards, right to your patient's inbox.

Document icon

IC Diet Guide

A handy guide to help your patients make “IC-smart” meal choices.

Document icon

Pelvic Pain & Urgency/Frequency (PUF) Questionnaire

Use the PUF Questionnaire to assess a patient’s condition initially and throughout the course of his or her therapy.

Document icon

O’Leary-Sant IC Symptom and Problem Index

Have patients complete this questionnaire that focuses on voiding symptoms to help in patient assessment.

Reprinted from Urology, Vol 49, O'Leary MP, Sant GR, Fowler FJ Jr, Whitmore KE, Spolarich-Kroll J, The interstitial Cystitis Symptom Index and Problem Index, Page 62, Copyright 1997, with permission from Elsevier.

Document icon

ELMIRON® Patient Brochure

Counsel patients about IC and what to expect from treatment with ELMIRON® using this informational brochure.

Document icon

ELMIRON® Symptom Journal

Highlight the importance of tracking IC symptoms in this convenient and easy-to-use journal for patients.

Adobe pdf

Download Adobe® Reader®
(The software you need to view PDF files)

Reference:

  • Kahn BS, Stanford EJ, Mishell DR Jr, et al. Management of patients with interstitial cystitis or chronic pelvic pain of bladder origin: a consensus report. Curr Med Res Opin. 2005;21(4):509-516.

IMPORTANT SAFETY INFORMATION

IMPORTANT SAFETY INFORMATION

  • Contraindications: ELMIRON® is contraindicated in patients with known hypersensitivity to the drug, structurally related compounds, or excipients.
  • Anticoagulant Activity: ELMIRON® is a weak anticoagulant which may increase bleeding. Rectal hemorrhage was reported as an adverse event in 6.3% of patients. Patients undergoing invasive procedures or having signs/symptoms of underlying coagulopathy or other increased risk of bleeding (due to other therapies such as coumarin anticoagulants, heparin, t-PA, streptokinase, high dose aspirin, or nonsteroidal anti-inflammatory drugs) should be evaluated for hemorrhage. Patients with diseases such as aneurysms, thrombocytopenia, hemophilia, gastrointestinal ulcerations, polyps, or diverticula should be carefully evaluated before starting ELMIRON®.
  • Heparin-Induced Thrombocytopenia: Caution should be exercised when using ELMIRON® in patients who have a history of heparin-induced thrombocytopenia.
  • Alopecia: In clinical trials of ELMIRON®, 97% of the cases of alopecia reported were alopecia areata, limited to a single area on the scalp.
  • Hepatic Insufficiency: ELMIRON® has not been studied in patients with hepatic insufficiency. Because there is evidence of hepatic contribution to the elimination of ELMIRON®, hepatic impairment may have an impact on the pharmacokinetics of ELMIRON®. Caution should be exercised when using ELMIRON® in this patient population.
  • Information for Patients: Patients should take the drug as prescribed, in the dosage prescribed, and no more frequently than prescribed. Patients should be reminded that ELMIRON® has a weak anticoagulant effect. This effect may increase bleeding times.
  • Pregnancy and Lactation: Adequate and well-controlled studies have not been performed in pregnant women. Because animal studies are not always predictive of human response, this drug should be used in pregnancy only if clearly needed. It is not known if ELMIRON® is excreted in human milk. Caution should be exercised when ELMIRON® is administered to a nursing woman.
  • Most Common Adverse Reactions (frequency 1% to 4%): Alopecia (4%), diarrhea (4%), nausea (4%), headache (3%), rash (3%), dyspepsia (2%), abdominal pain (2%), liver function abnormalities (1%), and dizziness (1%).

Please click here to read the full Prescribing Information for ELMIRON®

cp-59277v1

ELMIRON® is indicated for the relief of bladder pain or discomfort associated with interstitial cystitis.

INDICATION

ELMIRON® is indicated for the relief of bladder pain or discomfort associated with interstitial cystitis.

Janssen

© Janssen Pharmaceuticals, Inc. 2019. All rights reserved.

This site is published by Janssen Pharmaceuticals, Inc., which is solely responsible for its contents. This site is intended for use by healthcare professionals of the United States and Puerto Rico. Janssen Pharmaceuticals, Inc., recognizes that the Internet is a global communications medium; however, laws, regulatory requirements, and medical practices for pharmaceutical products vary from country to country. The Prescribing Information included here may not be appropriate for use outside the United States and Puerto Rico.

Third party trademarks used herein are trademarks of their respective owners.

Legal Notice | Privacy Policy | Medical Information Center | Sitemap | Sitemap 

Do not sell my personal information

Last Updated December 2019 cp-55422v4

The information contained in this section of the site is intended for US healthcare professionals only.